The Rotavirus Vaccine market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Rotavirus infection is the most common cause of acute gastroenteritis in children under 5 years of age in Kenya. In 2009, the World Health Organization recommended that all countries, especially those with high diarrhoea-associated child mortality rates, implement rotavirus immunization programs. Rotavirus vaccination was introduced into the Kenya Expanded Programme on Immunization (KEPI) in 2014. Two of the vaccines (Rotarix™ and Rotateq™),licensed by WHO are available in Kenya. Rotavirus vaccine has been well-received in Kenya due to the excellent clinical efficacy of both the vaccines. A substantial reduction of rotavirus-associated hospitalizations and all-cause diarrhoea has been observed in Kenya within 3 years of vaccine introduction.
The market is majorly driven due to the high burden of diarrhoeal infections among infants and children under the age of 5 years in Kenya. Age distribution of rotavirus prevalence was as follows: ≤ 6 months-8.5%, 7-12 months-27.4%, 13-24 months – 41.4%, 25-36 months – 16.4% while 36-65 months had 6.3%.
Rotavirus diarrhoea was more common in wet and cold months of the year, the highest prevalence being observed in August (24.5%) in Kenya.
With financial support from GAVI (Global Alliance for Vaccines Initiatives), Kenya introduced the two-dose RV1 into the national immunization programme in July 2014. The vaccine is administered orally at 6 and 10 weeks of age and the goal is to protect more than 1.5 million children in the country from developing severe acute gastroenteritis.
Increased support from international organizations like UNICEF for large scale vaccination, supply availability, and access to affordable prices is another factor fuelling the rotavirus vaccines market.